Too Cheap to Ignore: We are upgrading OSK to Buy from Hold, increasing our adjusted 2026-2027 EPS to $12.55 and $15.00, and raising our price target to $127 (from $93)—which implies 29% upside

Summary: Shares/adopts Truist upgrade of OSK to Buy, PT raised to $127 (29% upside) on cheap valuation, resilient earnings, and Defense bottom.

structural marker; pre-classified as canonical yfinance ticker

industry='Farm & Heavy Construction Machinery'

OSHKOSH $OSK upgraded to 'Buy' (from Hold) at Truist Securities, with a $127 price-target (from $93). Analyst Jamie Cook says the stock is "too cheap to ignore":

"Too Cheap to Ignore: We are upgrading OSK to Buy from Hold, increasing our adjusted 2026-2027 EPS to $12.55 and $15.00 (prev. $11.55 and $13.00), and raising our price target to $127 (from $93)—which assumes 7.0x our 2026 EBITDA estimate of $1.344B discounted back, and $11.0x our 2026 adjusted EPS estimate of 12.55 discounted back and implies 29% upside.

Oshkosh is the cheapest name within our Machinery coverage universe trading at 8.3x consensus forward earnings and 5.9x consensus forward EV/EBITDA, representing a ~40% discount to the broader Machinery group and screening cheap relative its long-term average. We believe the risk/reward is attractive given strength of the balance sheet, above average visibility supported by backlog in the higher margin Vocational business, and with Defense sales and margins at bottom.

We believe OSK earnings should prove more resilient relative to prior downturns. We believe that the overhang on the stock is that the downturn for Access Equipment extends to 2026, and the stock has priced in an aggressive bear case scenario."


Summary: Truist reiterates Buy on KTOS, raises PT to $78 from $52 on 20-30% revenue CAGR and 40-50% EPS/EBITDA CAGR through 2030.

KRATOS $KTOS price-target raised to $78 (from $52) at Truist Securities:

"We are reiterating our BUY rating and raising our PT to $78 from $52 on KTOS following our Blue Sky analysis which seeks to model the co's numerous unmanned, turbine engine and hypersonic opportunities through the rest of the decade.

Having already guided to 2026 rev growth of 13-15% we believe the co's next-gen centric portfolio has the potential to grow revenues at a 20-30% CAGR through 2030 unlocking 600-900bps of margin expansion which should lead to an EPS and EBITDA CAGR in the 40-50% range.

This note outlines our rev build assumptions through 2030, provides detail on all of KTOS's programs and platforms, and in our view justifies the company's premium multiple."


AMZN still top pick... Raise PT to $300 (35% upside) and $350 bull case (60% upside)

Summary: Morgan Stanley reiterates Overweight on AMZN, raises PT to $300 (from $225) on tariff relief and AWS acceleration; AMZN named top pick.

AMAZON $AMZN price-target raised to $300 (from $225) at Morgan Stanley, while maintaining an 'Overweight' rating.

Analyst Brian Nowak is raising his outlook in light of softer China tariffs:

"Raise '26/'27 EPS by 9%/6% for lower tariffs as $8 of '26 EPS returns as base case. Anthropic, Azure's GenAI and non GenAI strength as supply eased, and CIO survey give us more conviction in AWS acceleration ahead.

Raise PT to $300 (35% upside) and $350 bull case (60% upside). AMZN still top pick More Manageable Tariff and Geopolitical Backdrop = Re-Raising '26 EPS to $8...The macro backdrop has significantly improved since mid-April when we published last and reduced our AMZN estimates (1P/3P Retail, merchandise margins, logistics inefficiencies, advertising headwinds, etc) to best attempt to account for a 145% China tariff.

Today, we are re-raising our estimates as we adjust for the more constructive macro landscape with lower tariffs. All in, our '26/'27 EPS rises +9%/ +6% to $8/$9. Notably, our new $8 of '26 EPS is in-line with our $8 of '26 EPS in 1Q25 (prior to our 145% China tariff cut note)."


Summary: Holding LEU as a long-term nuclear theme position.

@UnoMasReactor Absolutely. Best theme. Hit $SMR for insane profits, keeping $LEU for long-haul..

@stocktalkweekly An insane run lately 🤘 nuclear has been on fire since the tariff lows


Summary: Goldman upgrades KTOS to Buy from Neutral, $52 PT, on defense drone/UAS/missile demand and medium-term top-line growth.

KRATOS $KTOS upgraded to 'Buy' (from Neutral) at Goldman Sachs, with a $52 price-target.

Analyst Anthony Valentini says they see "significant top-line growth over the medium term":

"We assume coverage of Kratos from Noah Poponak and upgrade the stock to Buy from Neutral with a $52 12-month price target. Kratos has strategically invested in areas of the defense supply chain that are critical to the future of warfare and are at a key inflection point. Funding is finally coming for drone programs, turbo jet and turbo fan engines are in high demand for UAS and missile systems, and both C5ISR and space are continuing to grow at a fast clip. Kratos is well positioned in these areas, and we expect the company's products to be in high demand as the defense industrial base is rebuilt. We see significant top-line growth over the medium-term, leading to expanding margins and improved cash generation."


Summary: Holding core long positions in nuclear and datacenter themes for the longer term based on sustained market signal.

NLR (VanEck Nuclear) and URA cover nuclear energy sector broadly.

@LogicalThesis Nuclear & datacenter have been my big winning themes this year AND last year. Market is saying something. Tells me I need to keep core positions in those thematics for longer term.

@stocktalkweekly Nice call on this one bro
This theme has been good to you
Along with others


Data center sector ETF proxies; DTCR (Global X Data Center) is primary.


Summary: Author claims early long call on LEU at $96, now at $196 with Stifel Buy/$220 PT; implies continued bullish stance ahead of consensus.

You could have read Stifel's initiation note on Centrus Energy $LEU this morning at $196...

... or you could have read my note on May 22nd of this year when the stock was $96

Ahead of the herd. https://t.co/lLHJ4ANlTR

CENTRUS ENERGY $LEU initiated at 'Buy' at Stifel, with a $220 price-target.

Analyst Stephen Gengaro says Centrus is uniquely positioned to build the U.S. nuclear supply chain:

"The atrophy of the U.S. nuclear supply chain is a key headwind for the resurgence in nuclear power in


Summary: Opened long WRBY on post-Google AI glasses partnership consolidation, with 200-day MA as stop.

industry='Medical Instruments & Supplies'

Opened a position in Warby Parker $WRBY this morning. Daily chart consolidating nicely after the Google AI glasses partnership. Using 200-day as stop. https://t.co/Nw1IYk2X1m


pounding the table that DraftKings has 30% upside after the deal to sell 5% of FanDuel for $2 billion

Summary: Shares Mizuho Buy reiterations on DKNG ($58 PT, 30% upside) and BYD, both underpriced relative to implied FanDuel $40B valuation.

DRAFTKINGS $DKNG reiterated at 'Buy' at Mizuho, with a $58 price-target.

Analyst Jed Kelly says he is "pounding the table" that DraftKings has 30% upside after the deal to sell 5% of FanDuel for $2 billion. He is also positive on Boyd Gaming $BYD after the sale:

"It is widely reported that BYD will sell its 5% position in FanDuel for $2bn. This implies a $40bn mkt cap for FanDuel. DKNG, which has similar market share in the United States, has a current market cap of $21bn. We believe DKNG should be materially higher on this news (vs up 2% as of this note). While we acknowledge there will always be some market value vs intrinsic value disconnect, we believe the mkt cap’s/valuation should largely be similar between the two companies.

Even if you assume a 30% haircut to the FD valuation, that would suggest ~30% upside to DKNG shares. Key Points Further, we believe $2bn for BYD (on 82m shares) is worth materially more than the market is pricing in (up ~5% over the last two days).

There are two considerations

(1) $2bn on 82m shares would suggest >$20/share of value. Even if the stock was up yesterday “inexplicably” (as has been the feedback thus far) it does not remotely capture the upside.

(2) we don’t believe BYD’s 5% position was priced in to shares intellectually. Regardless of sentiment, currently, BYD trades at 8x our forward EBITDA. That seems about right for a regional (Vegas locals) business that owns its real estate and, importantly, does not suggest that there is 5% of even $20bn (our expectation originally for FD) backed into the stock, much less 5% of $40bn."


we believe $2bn for BYD (on 82m shares) is worth materially more than the market is pricing in

Context references shares/market pricing for BYD the Chinese EV maker.


Summary: Bullish COUR: consolidating above 200-day MA with Microsoft AI education spend as a legitimate catalyst.

$COUR spent past 3 months consolidating above 200-day. Microsoft AI education spend is legitimate catalyst. Stock has range. https://t.co/Htq5D4BcRx


I'd go $LEU hands down (I currently own it). Only U.S. based uranium enricher using U.S. technology

Summary: Long LEU as the preferred nuclear play; only US-based uranium enricher, currently held.

@DoYouEvenLif If we’re gonna go nuclear, I’d go $LEU hands down (I currently own it). Only U.S. based uranium enricher using U.S. technology


Summary: Bullish GENI: endorses golden cross + record volume + gap-fill setup with a decisive upside conviction phrase.

industry='Internet Content & Information'

$GENI doesn't get prettier than this. All moving averages simultaneously crossing 200-week (including 50/200 golden cross). Highest daily, weekly, and monthly volume ever. Climbing into a big gap to the upside. https://t.co/ugpkUAs8dh


Summary: Oppenheimer initiates ATAI at Outperform with $14 PT on psychedelic neuropsychiatry pipeline and BPL-003 Ph2b data.

ATAI LIFE SCIENCIES $ATAI initiated at 'Outperform' at Oppenheimer with a $14 price-target:

"We initiate ATAI Life Sciences (ATAI) with an Outperform rating and $14 PT. We view ATAI as leading the psychedelic revolution within neuropsychiatry, which remains an under-appreciated market opportunity considering ~10M patients who could benefit from alternative approaches as unmet needs persist despite available therapies.

We believe Ph2b data for BPL-003 (intranasal 5-MeO-DMT) solidify a transformational approach based on rapid onset, durability, safety/tolerability, and convenient integration into existing clinical practice.

Our extensive KOL discussions suggest strong demand for this profile upon potential commercialization. ATAI's pipeline of pioneering psychedelic compounds provides diversification while remaining undervalued ahead of key catalysts.

We view ATAI as financially well-positioned and expect management to unlock value. We leverage our deep neuropsych expertise (e.g., AXSM, CMPS, MNMD, NBIX) to inform our analysis."


Raise PO to $22 on 16x EBITDA (from $20 on 15x), reflecting 1) upside potential to '25 estimates, and 2) increased confidence in '26 growth

Summary: Analyst reiterates Buy on MGNI, raises PT to $22 on upside to '25 estimates and confidence in '26 growth; EBITDA multiple expanded to 16x.

MAGNITE $MGNI price-target raised to $22 (from $20) while maintaining a 'Buy' rating.

Analyst Omar Dessouky discusses his fireside chat with the CEO and CFO fireside chat.

"On June 18, we hosted MGNI’s CEO, CFO, and SVP of Investor Relations for a virtual fireside chat where management updated us on some key observations at both the Upfronts season and Cannes Lions this year. Sentiment at both conferences appeared positive, and ad buyers have mostly shaken off tariff-induced concerns; mgmt expects both pricing and commitments to be on par with last year.

The industry’s transition to programmatic ads seems to be progressing well, with programmatic now taking up ~50% of conversations at the Upfronts & NewFronts combined (vs zero just 3 years ago). We came away from the discussion with greater conviction that MGNI should steadily outgrow the CTV ad industry over the mid to long term. Raise PO to $22 on 16x EBITDA (from $20 on 15x), reflecting 1) upside potential to ’25 estimates, and 2) increased confidence in ’26 growth."


Summary: Targets HOOD at $300.

@fatninjalife I love it! See you at $300 $HOOD

@stocktalkweekly Congrats

  $HOOD rock n roll🥰


Summary: Shares Evercore ISI Outperform on VRT with PT raised to $150 ($250 bull case) on AI data center TAM, liquid cooling, power management, and margin expansion.

VERTIV $VRT PT RAISED TO $150 AT EVERCORE ($250 BULL CASE)

Vertiv Holdings $VRT price-target raised to $150 (from $100) at Evercore ISI, while maintaining an 'Outperform' rating -- analyst Amit Daryanani outlines 5 bullish factors:

"VRT looks like a compelling way for investors to play secular trends related to AI data centers (hyperscale and beyond). While fixation on orders and noise around hyperscale digestion will cause volatility, we believe for those with a multi-year horizon, the underlying demand signals remain strong and there is potential for the stock to reach the $200+ range.

In our BULL case, VRT sustains high-teens revenue growth alongside ~30-35% incr. margins, enabling EPS CAGR of ~25% to >$10 EPS by CY29. Now, should VRT demonstrate consistent and less volatile EPS growth, the stock could support a multiple comfortably >20x. Conversely, if VRT reaches $10 EPS in a volatile and episodic manner, valuation may compress into mid-teens.

Our bullish bias is driven by [the following 5 factors]:

1) Attractive TAM: VRT continues to benefit from AI deployment acceleration and increasingly complex DC environments. Total TAM of ~$52B is growing at 9-12% CAGR, and we expect VRT to outgrow the market by 300-500bps with hyperscalers growing 20%+.

2) Services and Solution Provider of Choice: VRT’s services will become increasingly critical as data centers grow more complex. Capabilities including liquid cooling servicing and lifecycle managing enable VRT to act as a full-stack provider. With power & thermal becoming more interdependent, VRT is well positioned as an end-to-end solution provider. A shift to having 24/7 services staff on-prem strengthens VRT’s presence in N. America.

3) Liquid Cooling: As rack densities climb (Rubin requiring >600kW), shift to liquid cooling is accelerating. We expect liquid cooling to reach 30% of the total thermal management market by CY28.

4) Power Play: Beyond thermal, we see an even larger opportunity on power management particularly as AI DC demands more equipment but also shifts to higher voltage infrastructure to support racks (Rubin and transition to 800V HVDC).

5) EBIT Margin Upside: As VRT scales its integrated systems and modular solutions, we expect sustained leverage & margin expansion (>23% by CY28).

Net/net: VRT stands out as an integrated player capable of addressing the full stack of DC infrastructure needs – from power and thermal to integrated services and lifecycle support. As total GW deployed continues to rise & VRT’s content per MW expands, we anticipate an acceleration in sales and margins over next few years. Maintain OP but adjusting target to $150, with BULL CASE of $250."


Summary: Benchmark reiterates Buy on INDI, raises PT to $8 from $6 on ADAS ramp visibility, margin expansion, and clear path to profitability through 2029.

INDIE SEMICONDUCTOR $INDI price-target raised to $8 (from $6) at Benchmark

Analyst Cody Acree says Indie represents a "compelling investment opportunity":

"Yesterday, we had the opportunity to host indie’s CEO, Donald McClymont, and Mark Tyndall, EVP Corporate Development & Investor Relations for a virtual group investor meeting, where we came away increasingly encouraged by the company’s rapidly developing revenue growth potential.

Overall, we believe indie represents a compelling investment opportunity, driven by its specialized focus and growing leadership in the high-growth automotive ADAS market, particularly in radar and machine vision applications. indie's differentiated technology, robust design win pipeline, aggressive operational efficiency initiatives, and strategic positioning across global markets (including China) is set to drive significant revenue growth, gross margin expansion, and a clear path to sustained profitability.

Despite current macroeconomic uncertainty and prior shortterm program pushouts, indie looks to now be on the verge of realizing the first real revenue from its multi-year investment commitments, where once the ramp begins, these programs should begin to build on one another, leading to the company’s return to extendable multiple years of growth. With increasing confidence in its December targets, and trading at just 10.6x our likely conservative FY27 estimates, we reiterate our Buy rating and on our improved view of its ramp potential and long-term growth drivers, we are raising our Price Target to $8 from $6, or 26x our FY27 EPS estimate of $0.31.

Highlighted by no fewer than 10 separate professions of confidence in the company’s ADAS ramp finally beginning in Q4, which is then expected to build momentum into significant growth next year before continuing to grow through at least 2029, as longterm design wins steadily come to market. We are most encouraged by the company’s growing visibility and a significant increase in its confidence that the much-anticipated ramp of its high ASP, high margin, machine vision and radar programs are about to come to fruition, with one radar platform and two vision programs expected to begin to contribute to material revenue in its December quarter.

indie’s CEO expressed comfort with the Street’s current mid-$60 million revenue estimate and the company’s target of achieving EBITDA breakeven in the fourth quarter, saying that Street estimates are purposefully conservative through the second half and internal targets could point to upside potential, if things go according to plan. We believe the radar program ramp will initially be into a small number of models through its lead Tier 1 relationship, likely with Aptiv, although this is unconfirmed, and one of its two vision programs look to be planned for multiple models at BYD, easily China’s largest Auto OEM, where indie could earn $20-$30 of content per car.

In addition to its company specific drivers, INDI also sounded cautiously optimistic regarding the health of the broader automotive industry, and although the company acknowledged that industry SAAR slowed in May to about 15.7 million units, down from April’s strong pre-tariff 17.3 million, May’s sales grew 3.2% annually and 2025 industry estimates are for about 16.3 million units, up about 3% year-over-year."


$MTRN quietly six green sessions in a row...

Summary: Shares bullish momentum on MTRN: six consecutive green sessions, KeyBanc $112 PT as undiscovered US rare metals/Beryllium play.

industry='Other Industrial Metals & Mining'

$MTRN breaking over 200-day & pushing into 200-week & 50-month simultaneously today.

KeyBanc out this AM with $112 PT identifying it as an undiscovered name in U.S.-based rare metals as the Western hemisphere's only Beryllium player. Niche market, but strategically important. https://t.co/778HLYgBUD


Summary: Still holding full position in GENI.

@ZaStocks Still full size on $GENI for me, and I also have an intriguing short interest basket i’ve built too that I like a lot. Lots of great setups out there rn

@stocktalkweekly Insane performance brother, consistent alpha from you. Let’s hope $GENI eventually boosts that up even further.


initiated at Craig-Hallum with a new Wall St.-high $75 price-target ... Craig-Hallum sees long-term upside to $200/share

Summary: Craig-Hallum initiates SPHR with Wall St.-high $75 PT and long-term $200 upside, disrupting traditional venue model.

SPHERE $SPHR initiated at Craig-Hallum with a new Wall St.-high $75 price-target

Analyst Ryan Sigdahl says Sphere is disrupting the traditional venue model with original 'Sphere Studios' shows & advertising via 'Exosphere'. Craig-Hallum sees long-term upside to $200/share.


Summary: Still long CIFR and RIOT as BTC-related plays; NBIS held as a core position from $23.92.

@CrypticMystiq Yes. Traded $IREN calls for +500%, and still long $CIFR $RIOT -- $NBIS is a core position from $23.92 if you want to count that one, too.

@stocktalkweekly Have any BTC and/or BTC related plays (treasury companies, miners, alts etc.) in there?


we opened a position in Bloom Energy $BE ... If it confirms breakout, can see $25 fast

Summary: Long BE; opened position last week, stock broke above 100-day MA with golden cross, targets $25 fast on confirmed breakout.

Last week on June 5 we opened a position in Bloom Energy $BE

Stock pushed +6.5% into the end of the week to close above 100-day after consolidating around 200-day for 2 months. Golden cross on weekly chart.

Short-interest at 25%. If it confirms breakout, can see $25 fast. https://t.co/hdGgBl2AQZ


Summary: RBC reiterates Outperform on Bloom Energy with $26 PT on electricity demand growth, co-location solutions, and cost-down initiatives.

BLOOM ENERGY $BE reiterated at 'Outperform' at RBC Capital, with a $26 price-target:

"Key takeaway: BE remains confident in the long- and short-term opportunities that are being supported by the backdrop of increasing electricity demand, grid constraints that make co-location solutions increasingly attractive, and internal self-help initiatives that are resulting in product cost-downs.

Mgmt addressed concerns around regional policy and indicated that the AEP announcement last year was a catalyst to accelerate conversations with other utilities. CHP solutions and International markets could be attractive opportunities going forward."


Summary: Holding KTOS 2027 LEAPS to expiration with no intent to sell; strongly bullish on Kratos long-term.

I'm going to post an update on these Kratos $KTOS leaps in January 2027 (and probably a few along the way).

I haven't sold any (which is extremely rare for me for options that are up this much) and won't sell any until expiration. https://t.co/XC4nOxlcjx

Kratos $KTOS breaking out of a 25-YEAR price range with highest-ever volume & extreme thematic relevancy (drones, autonomous weapons, hypersonic/supersonic engines).

I have been pounding table, stock is +80% YTD & my 2027 leaps are up +250%. Not selling any. Wake me up at $100. https://t.co/RIMnGoGPUu


Summary: Bullish TSLA: Elon back as 'Destroyer of Shorts' following successful Austin FSD testing ahead of schedule.

@elonmusk Now that the special government employee tenure is over, Elon has officially resumed his title as 'Destroyer of Shorts'

https://t.co/7qEZcePJf4

For the past several days, Tesla has been testing self-driving Model Y cars (no one in driver’s seat) on Austin public streets with no incidents.

A month ahead of schedule.

Next month, first self-delivery from factory to customer.


Summary: Shares/endorses Benchmark Buy reiteration on KTOS with PT raised to $48, driven by $600M+ incremental defense funding and hypersonics/drone demand.

KRATOS $KTOS price-target raised to $48 (from $40) at Benchmark, while maintaining a Buy rating.

Analyst Josh Sullivan discusses the company's immediate contract opportunities:

"Net-net, we are raising our PT to $48 from $40 given

1) Defense Budget Reconciliation Bill details that point to KTOS programs receiving +$600M of incremental funding

2) This past week’s Iranian geopolitical tactics highlight KTOS’s portfolio value in future conflicts [hypersonics/long-distance munitions, drones, & ISR]

The released Senate Armed Services Reconciliation bill includes incremental funding of $270M for Marine Corps unmanned combat aircraft and $400M for the Multi-Service Advanced Capability Hypersonic Test Bed. KTOS has been working with the Marines on the Valkyrie drone since 2022, and just expanded the relationship with a $35M contract this past January.

The Marines have long been thought to be the first likely adopter of the Valkyrie, and a $270M funding increase could provide an order of magnitude for 30-50 aircraft depending on allocations. In January, KTOS also won the 5-year $1.45B MACH-TB 2.0 (hypersonic test bed) contract, and therefore, +$400M funding would be well ahead of expected time-lines. The increasing use of hypersonics to by-pass traditional air defense systems will be a feature of future combat as we have seen this past week.

The $1.5B MACH-TB contract, and funding upsizing, dictates KTOS will be front and centre testing U.S. multi-service offensive and defensive hypersonic capabilities for years to come. The President’s “Big Beautiful Bill” is expected to be signed in July, and the nature of the Iranian engagement highlights KTOS important positioning within future combat scenarios."


Most people fail to understand how much more significant an expansion of pure vision autonomous area is vs. an expansion of lidar-enabled autonomous area. one is substantially more cost-effective to both deploy & scale.

Summary: Bullish TSLA: pure-vision autonomy expansion is far more cost-effective to deploy and scale than lidar-based rivals, making the Austin expansion more significant than markets realize.

Most people fail to understand how much more significant an expansion of pure vision autonomous area is vs. an expansion of lidar-enabled autonomous area.

Yes, they both accomplish effectively the same thing, but one is substantially more cost-effective to both deploy & scale.

@Gfilche @robotaxi Expanding to a larger service area in Austin this weekend


Summary: Bullish KTOS via 2027 LEAPS calls.

@pennycheck 2027 leaps are cooking ;) https://t.co/wRl0ESYvI7


Summary: CRSP breaking above 200-week MA on record weekly volume; bullish technical breakout signal.

$CRSP breaking over 200-week moving average today behind highest-ever weekly volume 2 weeks ago https://t.co/ZyjNrvFmDI


Summary: Strongly bullish on an unnamed mid-cap uranium/nuclear-related asset amid Israel-Iran conflict and nuclear energy renaissance.

URA is the standard ETF proxy for uranium commodity exposure.

@UnoMasReactor Fantastic news! With this Israel-Iran conflict centered around enrichment in the backdrop and the nuclear energy renaissance in the forefront, I continue to believe this is one of the most valuable mid-cap assets on earth!


My favorite nuclear name. Recently re-entered at $96 on 5/22, been holding strong since.

Summary: Holds LEU long since re-entry at $96, up 40%, still holding strong.

@JSpitTrades My favorite nuclear name. Have owned & traded it for last several years many times. Recently re-entered at $96 on 5/22, been holding strong since. Already +40% on shares 🔥

https://t.co/PVMNJFymRR

$LEU is acting fantastic

Dip into rising 10d SMA was bought up

+2.8% on the day after

A top nuclear name. https://t.co/ppWrZbtO6h


Summary: Bullish CXW: detention centers filling, ICE raids accelerating, tight chart, solid guidance; ICE is 30% of revenue.

industry='Security & Protection Services'

CoreCivic $CXW - Despite their spat, Trump & Elon remain on the same page about border security.

Reports last week that detention centers are filling up & ICE raids accelerating. Chart is tight & solid guide last quarter. ICE is CoreCivic's largest client (30% of revenue). https://t.co/Di8Bdb6PoO


Summary: Long ACHR via July & October $10 calls, backed by ARK 4.6% stake disclosure and eVTOL executive order catalyst.

On Friday, about 40 minutes before market close, we opened a position in Archer Aviation $ACHR $10 calls for July & October

After the close, ARK disclosed a 4.6% stake, combined with the eVTOL executive order catalyst from last week.

Chart is promising on all time frames. https://t.co/3Z9cDDmjBu

---

For those who said “I don’t believe you alerted a position on Friday before close” here you go, lol. Time stamp in CST https://t.co/2efWTuqM2U


Summary: Holding long-dated 2027 LEAPS on KTOS; expects continued gains on upcoming catalysts.

@MagicShortBus00 My 2027 leaps should continue to print 😉

@stocktalkweekly Well well well.. more catalysts coming out for our longs eh? $KTOS


Summary: Shares BofA Buy reiteration on AMZN with PT raised to $248 on robotics/AI efficiency gains and margin expansion potential.

AMAZON $AMZN price-target raised to $248 (from $230) at Bank of America, while maintaining a 'Buy' rating. Analyst Justin Post says Amazon now has 750K robots assisting with 75% of customer orders:

"Amazon’s robot capabilities have ramped since the Kiva acquisition in 2012, and Amazon now has over 750,000 robots assisting with 75% of customer orders. Still, with AI capabilities ramping, Amazon’s first 12th Gen. automated fulfillment center (FC) launched in late-2024, and eight new robots just announced in May that are primarily focused on delivery station efficiencies, the robotics cycle is early.

Going forward, we expect Amazon to leverage robots to: 1) reduce labor dependency; 2) increase order accuracy; and 3) improve warehouse efficiency, driving material cost savings. Amazon’s 2024 Retail operating profit margin of 5.4% has made big progress since ‘22 and we see long-term potential retail margins at 11% assuming a 55% margin on advertising, 20% on 3P services, 5% for subscriptions, breakeven 1P, and $10bn in annual investment spend.

We think robots and drones will increase Amazon’s shipping speed advantages, and could add another 2pts to Amazon’s long-term retail margins, helping move 1P toward better profitability in a very price-transparent AI world. Raise PO to $248 on recent SaaS and retail sector multiple expansion and reiterate Buy."


Summary: Rosenblatt more than doubles MGNI PT to $39 on substantial AdTech antitrust remedy benefits not yet reflected in equity, as early as 2026.

MAGNITE $MGNI price-target more than doubled to $39 (from $18) at Rosenblatt:

"Magnite's benefit from the upcoming AdTech antitrust remedy/penalty phase is likely to be very substantial, very possibly as early as early 2026, and in our view is not reflected in the equity. We move to close that gap, by using what we see as conservative and beatable antitrust assumptions, from both likely EBITDA lift from behavioral remedies, and proceeds from civil litigation/potential settlement, to raise our Magnite price target $18 to $39. Underlying this analysis is our belief that the ruling against Google was strong, and is likely to withstand potential appeals."


SOUNDHOUND AI $SOUN INITIATED AT 'OVERWEIGHT' AT PIPER SANDLER WITH $12 PT

Summary: Piper Sandler initiates SOUN at Overweight with $12 PT; author shares/adopts the bullish rating.


Summary: Author picks ASTS, KTOS, and ERJ as next top names in their aerospace & defense basket.

@LogicalThesis Very true, if this list was 6 names $ASTS $KTOS $ERJ would be the next 3. To be honest, my aerospace & defense basket also deserves a lot of credit for the stability in the portfolio in the first half of the year.

@stocktalkweekly You killed it on ASTS too


Summary: Goldman Sachs raises HOOD PT to $91 from $82, reiterates constructive view on long-term structural growth.

ROBINHOOD $HOOD price-target raised to $91 (from $82) at Goldman Sachs

Analyst James Yaro says Robinhood "continues to launch new products and expand geographically", but cites caution about June volumes:

"HOOD reported mixed June monthly metrics, which imply higher equity and option volumes than Visible Alpha Consensus data (albeit lower than GSe), and lower crypto volumes than GSe & consensus. Against this, HOOD continues to launch new products and expand geographically, and we take a more constructive view on long-term business growth - as such, our 2025E/26E EPS estimates fall 7%/3%, although they remain 2%/1% above the Street.

June HOOD estimated volumes for equities/options/crypto were -2%/-9%/-30% vs. GSe (we adjust DARTs by the number of trading days remaining in the month, based on reported data through 6/24), and +52%/+12%/-16% vs. the Street-implied number. We now expect June volumes across products to be roughly flat to down MoM (equities/options/crypto -2%/-8%/-25%), indicating modest pressure on retail trading activity in the month. We remain constructive on HOOD's structural growth."


Summary: Benchmark reiterates Buy on QBTS, raises PT to $20 from $14 on Yonsei University MOU and growing on-prem quantum hardware pipeline.

D-WAVE QUANTUM $QBTS price-target raised to $20 (from $14) at Benchmark, while maintaining a Buy rating.

Analyst David Wailliams comments on the MOU with South Korea's Yonsei University:

"D-Wave announced the signing of a memorandum of understanding (MOU) with South Korea's Yonsei University and Incheon Metropolitan City to accelerate quantum computing adoption. We view this as a significant strategic step that validates D-Wave's technology on a global stage and, most importantly, establishes a clear framework for the future sale and installation of an Advantage 2 quantum system. While the MOU is nonbinding, it explicitly states the parties will work towards the acquisition of a system, representing a potential double-digit million-dollar revenue opportunity for the company and anchoring D-Wave's ecosystem strategy in a key, tech-forward market.

The first hardware sale to Julich was said to be driven by the Quantum Supremacy results D-Wave demonstrated on it prototype Advantage 2 system, and we estimate the sale generated ~ $15M of revenue. The company noted pipeline of potential sales opportunities was healthy, but timing was uncertain, with additional sales not contemplated in the annual guidance. We believe this announcement signals a growing interest for on-prem quantum hardware solutions, which has the potential to significantly pull forward the revenue growth trajectory. While QCaaS remains the primary longer term revenue driver, the near-term H/W opportunities help reduce cash burn while also generating longer term QCaaS revenue optionality. If the sale is completed this year, we estimate cash usage would decline to ~$45M in FY25 vs $61M last year, despite the 26% increase in OpEx.

This partnership is a notable strategic win, embedding D-Wave directly into South Korea's national ambition to become a global quantum leader. South Korea has committed approximately $1 billion over the next several years to boost its quantum capabilities, and this MOU positions D-Wave as a key technology partner in that effort. By collaborating with a top-tier research institution like Yonsei University and a government body like Incheon Metropolitan City, we think provides significant credibility and gains access to a meaningful geography. The agreement to establish a "quantum cluster" focused on Incheon's strong biotechnology and industrial sectors offers an opportunity rich environment for developing real-world applications, which is critical for demonstrating value and driving broader commercial adoption of D-Wave's annealing quantum computers."


Summary: Holds WRBY long from $20.27; stock at $21.50, expects explosive move above $22.20 on record volume breakout.

Warby Parker $WRBY quietly working well since we opened our position on May 29 at $20.27

Stock is now $21.50 (+6%), and building well. Never came close to our 200-day stop. Can be explosive over $22.20. May was the highest-ever monthly volume for the stock (by quite a margin). https://t.co/jzUWN77HY8

Opened a position in Warby Parker $WRBY this morning. Daily chart consolidating nicely after the Google AI glasses partnership. Using 200-day as stop. https://t.co/Nw1IYk2X1m


Summary: Bullish NVDA: Q2 guidance ex-H20 impairment implies $53B blowout; market reaction positive.

Nvidia's Q2 guidance was very strong when you factor in the -$8B impairment for H20. At the midpoint, Nvidia guided Q2 revenue at $45B, which was slightly below expectations, but without the impairment it would have been $53B which would be a blowout. The market likes that $NVDA


Summary: Citizens JMP reiterates Outperform on CRSP, PT $86, citing in-vivo asset upside and positive gene-editing M&A read-across.

CRISPR THERAPEUTICS $CRSP reiterated at 'Outperform' at Citizens JMP, with an $86 price-target:

"Today's gene-editing M&A deal is an important milestone for the technology. Eli Lilly (LLY, NC) and Verve Therapeutics (VERV, NC) have already collaborated, but the premium is a positive and timing is of interest, given early clinical-stage platform technology bios have not seen much interest lately.

Overall, the alignment of strategic interest in gene editing and a simultaneous focus by regulators (and MAHA) on one-and-done "cures" is a strong positive that can rally the sector. Investor pushback has been on reimbursement and market uptake, but we believe the attractiveness of one-time therapies, even in indications with options like HAE or ATTR, are underestimated. We view positive read-across to all gene editors.

On CRSP: The company has received very little valuation contribution from its in-vivo assets. CRSP recently unveiled data on its first of several in-vivo programs, with a single dose of CTX310 showing dosedependent decreases in ANGPTL3, and with best-in-class peak TG and LDL reductions. With VERV valued at $1B+ for similar indications, we see potential upside as CRSP makes progress. We expect an FiH update from CTX320 (second CV program targeting Lp(a)) this month."


Summary: Stifel raises RKLB PT to $34 from $29, maintains Buy on Geost acquisition expanding into satellite payload segment.

ROCKET LAB $RKLB PT RAISED TO $34 AT STIFEL

Rocket Lab USA $RKLB price-target raised to $34 (from $29) at Stifel, while maintaining a Buy rating.

"After the close, Rocket Lab announced an agreement to acquire Geost, LLC, an electro-optical and infrared payload development and manufacturing company and provider to high-priority national security satellites for $275M ($125M in cash and $150M in privately placed shares of RKLB, with an earn-out of up to $50M tied to revenue targets).

The transaction is expected to close sometime early in 2H25 and has already been approved by both company boards of directors, but is subject to regulatory (HSR) and standard closing requirements. While no GAAP information was provided, management believes the deal will be neutral to moderately accretive to its adjusted EBITDA in the 2H25.

We are encouraged by this latest announced deal, and its strategic rationale where Rocket Lab is acquiring key technologies to enter into the satellite payload segment, creating a new category and positioning the company as a disruptor for national security space."


Summary: TD Cowen upgrades HII to Buy, PT $300, on sizable margin upside to 9-10% and promising upcoming contract signings.

HUNTINGTON INGALLS $HII upgraded to 'Buy' (from Hold) at TD Cowen, with a $300 price-target.

Analyst Gautam Khanna says margin upside is sizable and upcoming catalysts are promising:

"(1) Eventual Margin Upside Is Sizable - HII's shipbuilding margin troughed at 5.2% in C24, dragged by post-COVID struggles (attrition, low productivity, cost overruns on fixed-price contracts) that are reminiscent of the post-Katrina nadir. HII mgmt asserts that 9-10% ship margin is realistic, as COVID-impacted boats drop as a % of a mix. The margin bogey is plausible, perhaps by C29, given HII's post Katrina history (9% avg over C13-20; 10.9% peak in C16), the Navy's willingness to bear more risk on new contracts, and industry/HII initiatives that should bolster retention and subcontractor performance. We model C25E ship margin of 6%, so the headroom – an eventual 50% margin lift – stands out vs. defense peers that have less of margin gap vs. entitlement.

(2) Upcoming Contracts Seem Promising - HII is in talks for 10 VCS Block 6 subs and 5 Columbia Class subs (GD is prime), and expects signings by 12/31. These signings could double HII's ship backlog ($42B) by 12/31. HII will commit only if terms inoculate it vs. uncontrollable costs, such as unforeseen labor escalation (NNS union contract expires in '27), supplier inflation, etc. The Navy seems amenable, a sharp contrast to its historical posture, which required sharing or eating of cost overruns. HII is using actual costs experienced during/since COVID as a "baseline" from which to price future work. Ship COGS are split roughly 40%/30%/30% between overhead/labor/suppliers, and labor/supplier costs have risen >30% (our est) since pre-COVID. HII is endeavoring to pare overhead costs ($250MM this year), and there will be negotiation over learning curve (labor hours, etc.). Beyond C25, contract opportunities are CVN-75 RCOH ('26), 2 more CVNs (advanced procurement; '27), and 10 DDGs (circa '28).

(3) Valuation & Broader Context - The Admin has raised threats to defense "incumbents" (DOGE, F-35 cuts, pivot from Europe) but has been supportive of U.S. shipbuilding. For example, HII doesn't seem at risk of major displacement from upstarts/unmanned vessel providers, a contrast to Trump's 1st term. HII's stock trades at a >20% discount to the S&P, despite extended, visible demand, big margin headroom, and huge entry barriers."


Summary: Still holding HOOD, LEU, and NBIS as top return drivers this year.

@themarketradar Three stocks have driven most of my returns this year, and yes Robinhood $HOOD is one of them.

The other two are Centrus Energy $LEU and Nebius $NBIS

@stocktalkweekly is this what $HOOD and chill looks like?


The other two are Centrus Energy $LEU and Nebius $NBIS


Summary: Bullish ASTS on weekly chart consolidation with strong volume profile and high short interest; expects next leg higher after EMAs catch up.

AST Spacemobile $ASTS potentially explosive consolidation on the weekly chart with a fantastic volume profile and high short-interest. https://t.co/p0RGH0oVQm

---

Worth noting that daily chart is a bit extended, so you should expect high volatility and some frustrating chop as this builds (which is nothing new on this name). Would ideally like to see 9/21EMAs catch up before next leg higher. https://t.co/e1w9dEFTs3


Summary: Apple reportedly replacing Google Search and ChatGPT with Perplexity on iPhone — bearish for GOOGL, potential positive for AAPL's AI independence.

*APPLE IS REPORTEDLY PLANNING TO ADOPT 'PERPLEXITY' AS AN ALTERNATIVE TO GOOGLE SEARCH ON THE IPHONE, AS WELL AS A REPLACEMENT FOR CHATGPT INTEGRATION FOR SIRI $AAPL $GOOGL


Summary: Rosenblatt initiates IONQ at Buy with $70 PT on quantum computing market leadership, $100M+ 2025 revenues, and roadmap execution.

IONQ $IONQ coverage initiated at Rosenblatt, with a $70 price-target:

"We are initiating coverage of IonQ (IONQ) with a Buy rating and $70 12-month price target. We believe IonQ provides an attractive way to gain exposure to the quantum computing market, a market that we see as the next era of computing.

It is our view that the quantum computing market is setup to be a multiple winner market and not a winner takes all market. We have a high level of confidence that IonQ is well positioned to take its place among the winners, and unlike some early stage competitors, IonQ will be exiting 2025 with annualized revenues in excess of $100M, nearly doubling in 2026, and could well be on track for $1B in revenue over the next few years.

We believe executing on the product roadmap, developing a quantum ecosystem to capture value in the nascent quantum networking, and increasing partnerships/system sales will drive stock price appreciation. Our 12-month price target of $70 equates to a 36.6x EV/S multiple on 2030 revenue discounted back."


Summary: Holds LEU long, not selling; endorses bullish thesis on HALEU commercialization and AI-power demand.

@stocktalkweekly LEU has the potential to reach 15-20 billion, driven by AI-power + reindustrialization, first-mover advantage in HALEU commercialization, and domestic substitution of nuclear fuel. It's hard to imagine—ur country has the world's largest nuke capacity, yet the nuclear fuel supply


Summary: Holding LEU as core position; unique uranium enrichment exposure amid Israel-Iran conflict keeps it bid while other nuclear stocks pull back.

Most nuclear stocks pulling back today with the market, but our core position Centrus Energy $LEU is still green.

Why? The Israel-Iran conflict is centered on uranium enrichment, and $LEU is the ONLY uranium enrichment play on the market.

Shares up +78% in under a month 🔥 https://t.co/NvHM5DfBQE

Centrus Energy $LEU up another +6% today, shares now up +43% from our $96 entry on May 22nd.

When you’re the world’s only publicly traded enriched uranium stock, the bids are strong & fast 🔥 https://t.co/8DTurP8ZN0


Summary: TD Cowen raises META PT to $800 from $700 on accelerating ad growth, above-consensus Q2 estimates, and easing tariff concerns.

META PLATFORMS $META price-target raised to $800 (from $700) at TD Cowen.

Analyst John Blackledge says Q2 2025 ad check showed accelerating growth:

"We forecast 2Q total revenue of $45.4BN, +16.1% y/y, 1.8% above consensus est. and vs mgmt guide of $42.5BN-$45.5BN. We estimate reported adv. revenue of $44.5BN, +16.1% y/y vs. +16.2% y/y in 1Q25. We expect opex grows 13.3% y/y in 2Q25, driven in part by headcount growth, cont'd AI investments, and rising D&A expense. We estimate 2Q Op Inc of $17.9BN, +20.7% y/y, 6.5% above consensus and implying an Op Inc margin of 39.5%, vs. 38.0% in 2Q24. We forecast 2Q25 GAAP EPS of $6.08 vs. cons est. of $5.82.

Our 2Q25 Digital ad expert check showed accelerating spend growth across Meta properties, per our agency. Growth was driven largely by robust impression growth at FB and solid pricing growth at Instagram. See details below.

We left our '25 est's unchanged, supported by cont'd engagement gains and improving video monetization, while raising '26-'30 estimates and lowering our discount rate as tariff concerns have eased since their April introduction. Our DCF-based PT goes to $800 from $700."


Summary: Shares Needham Buy reiteration on RIOT with PT raised to $15, citing Corsicana HPC site potential.

RIOT PLATFORMS $RIOT price-target raised to $15 (from $12) at Needham, while maintaining a Buy rating.

Analyst John Todaro says Riot's Corsicana site is one of the most attractive HPC sites in their universe of coverage:

"We believe Riot's Corsicana site is one of the most attractive HPC sites in our universe. In recent checks with neo-cloud operators, we learned that more than half of demand is for inference workloads (and growing), which mostly require sub 5ms rd trip latency to the nearest major city.

Corsicana is the largest site in our universe that can support these workloads (1GW total; 600MW gross NT, ~440MW critical IT), located near Dallas replete with add'l fiber, water access, and more than 630 acres.

Mgmt. is laser focused on transitioning to HPC, and we expect advanced discussions with prospective tenants in 2H '25, but the earliest a lease would come is 1H '26. In a hypothetical lease, we believe Corsicana would contribute $12-16 in share price. We are not modeling a Corsicana lease at this time, but raise our PT to $15 on a higher multiple."


Summary: Agreeing ASTS is just getting started; exercising $25 calls tomorrow.

@JSpitTrades I agree. Exercising these $25C tomorrow.

What if I told you...

... that $ASTS was just getting started? https://t.co/vGAmSMl3H6


We remain Overweight, following today's Q2 results... we would welcome any theories... The financials were solid... we don't really care what Tesla's next product looks like

Summary: Wall St earnings roundup: Piper ($400 OW), Mizuho ($375 OP), Canaccord ($333 Buy) all bullish; Baird/Truist/Barclays Neutral and UBS Neutral ($215) flag near-term fundamental headwinds.

WALL ST. COMMENTS ON TESLA $TSLA EARNINGS

PIPER SANDLER - 'OVERWEIGHT' - $400 PT: "We remain Overweight, following today's Q2 results. TSLA is indicated lower by ~5% in after-hours trading, but we're not sure why (we would welcome any theories). Yes, there's no "traditional" valuation support at this level, but that was the case before the call. So what changed? The financials were solid, so that's not the issue. Perhaps people are misinterpreting Elon Musk's comment that a coming new product will look exactly like Model Y. We can see how that might be disappointing, but in the context of FSD, we don't really care what Tesla's next product looks like. Elon also predicted difficult quarters ahead, as U.S. government support wanes. But if half the U.S. population will have access to unsupervised FSD by 2026, a difficult quarter in 4Q25 shouldn't matter, either."

MIZUHO - 'OUTPERFORM' - $375 PT: "TSLA reported inline 2Q25E Rev/EPS of $22.5B/$0.40 (vs. cons. $22.6B/$0.42). Auto GMs ex-ZEV credits better at ~15% vs. cons. ~13.3%, up 250bps q/q. TSLA did not guide 2025E deliveries noting 'shifting global trade and fiscal policies'. 2Q25 deliveries were dn ~14% y/y, as we estimate full-year 2025E at dn 11% y/y though 2H25E slightly better with NA test drives up 20% q/q. TSLA noting EV subsidy end in SepQ could see potential for some 'rough quarters in 4Q25/1H26E' with need to drive affordability/sales in the absence of subsidies. Maintain Outperform, PT $375, adjust estimates, as we see TSLA positioned well to disrupt AV and Robotics despite near-term EV demand headwinds."

CANACCORD - 'BUY' - $333 PT: "We are raising our PT from $303 to $333. This target is based on ~38x our 2027E non-GAAP EPS of $8.77. We feel this multiple is justified based on the multiples and growth rates of Tesla’s comp set — which we deem to be a group of megacap tech stocks, including Alphabet, Amazon, Apple, Meta, Microsoft, and Nvidia. This set of companies trades at a median of ~24x 2027E EPS (FactSet) but has a combined revenue growth rate materially below Tesla’s from 2025 - 2027. Longer term, Tesla has a generational set of growth opportunities ahead, including EVs, autonomy/AI, energy storage, and robotics, which also help justify our premium multiple. We acknowledge the limited upside implied by our price target. However, we believe BUY is the appropriate rating given near-term volatility buttressed by the long-term opportunities beyond the next 12 months."

BARID - 'NEUTRAL' - $320 PT: "TSLA reported slightly better than consensus estimates that have been lowered following the Q2 delivery release. The strength of the Energy business’s profitability was the biggest surprise in the financials. Commentary was mixed with Musk providing outlook/timelines for robotaxi (again) while pushing some timelines, e.g., Optimus. The big question is how long does TSLA get a pass on timelines? TSLA is working on revolutionary products such as Robotaxi, Optimus, and Dojo, but we remain at a Neutral rating as we think the near term financials will become the focus."

TRUIST- 'NEUTRAL' - $280 PT: "TSLA's Q2 was noisy, but revs & EPS were inline. Mgmt acknowledged that tariffs, and changes to consumer & regulatory credits could drive revenue, EPS, & FCF lower in the next few qtrs, potentially draining some of TSLA's $37b cash position. The company offered remarkably little detail on some of the most important factors like the new lower priced vehicles, FSD, Dojo, & Optimus, making our outlook lean more on imagination than realistic targets. So, our medium & long-term outlook on these matters is unchanged. Our DCF PT stays $280"

BARCLAYS - 'EQUALWEIGHT - $275 PT:  "On one hand, Elon Musk reiterated that Tesla’s future is far beyond the automotive business, with efforts in AI paving the opportunity for Tesla to be the most valuable company in the world. Elon reminded us that Tesla is the clear global leader in real-world AI driven by efforts in Robotaxi and Optimus, with Tesla a clear leader in “intelligence density.” Elon is working on a new “master plan,” articulating the transition from a pre-autonomy to post-autonomy world. Moreover, the potential exists for Tesla to “link arms” with xAI, reinforcing Tesla’s efforts in AI. Alongside comments of expansion in Robotaxi, we believe the narrative remains intact.

Yet while the AI narrative remains intact for Tesla, the call reminded us that fundamentals remain choppy, and are likely to deteriorate in the coming quarters. With the expiration of the US EV tax credit at the end of 3Q, Elon Musk noted there could be a few “rough quarters.” Moreover, Tesla also talked to reduced regulatory credit sales related to modified emissions standards. The impact of tariffs will magnify. And lastly, while the new low-cost model was effectively pushed to 4Q, we still see likelihood that it is a decontented Model Y…begging the question of how much incremental demand it will spur."

UBS - 'NEUTRAL' - $215 PT: "The near term fundamental outlook for TSLA remains challenged. The company is facing the end of the $7.5k consumer EV credit in the US, which will likely be a drag on demand, the brand continues to have challenges in Europe and China remains competitive. Yes, there are 'new models' but these are really Model Y variants which could limit incremental demand. We now model 2026 deliveries at 1.62mm (+8% y/y) and -18% below consensus at 1.98mm. Further, TSLA will likely lose a large portion of their EV credit revenue, which is 100% margin accretive, and should weigh on profitability into next year. All in, we are lowering our 2026 EPS to $1.85 from $2.24. However, at the same time, the vision of TSLA as the leading player in robotaxis and humanoids is in its infancy and the ventures are progressing. The stock always remains a battle between what can be and what is. Post earnings, we see negative revisions to estimates, which could weigh in the near-term. Bulls will continue to look past valuation, look for evidence of AI progress and dream big."


Maintain Outperform, PT $375, adjust estimates, as we see TSLA positioned well to disrupt AV and Robotics despite near-term EV demand headwinds


We are raising our PT from $303 to $333... we believe BUY is the appropriate rating given near-term volatility buttressed by the long-term opportunities beyond the next 12 months


Summary: Citizens JMP reiterates Market Outperform on GENI, raises PT to $13 on duopoly position, recurring revenue, and 24% CAGR in-play gaming growth through 2030.

GENIUS SPORTS $GENI price-target raised to $13 (from $12) at Citizens JMP:

"We maintain our Market Outperform rating and increase our price target to $13 (from $12) on Genius Sports following our investor meetings in Chicago, IL, and Milwaukee, WI. Our $13 price target is based on 17.8x our 2026E EBITDA (from 17x).

The company sits within a true duopoly and is tied to long-term data rights agreements with leagues and federations. Revenue has become largely recurring as international contracts (62% of TTM revenue) are fixed, subject to escalators, and collectively increasing 10% to 15% in a given year.

In the U.S., the company is also tied to minimum revenue guarantees while benefiting from the upside (variable) when sports betting operators exceed expectations in a given period, or spend beyond the contractual minimums for Genius technology. The clarity and certainty around the revenue highlight to us why the company is one of our favorite ways to own the online gaming space.

In our view, the core business (betting) should see upside to estimates in the coming years as more wagering shifts to in-play betting (currently 30%), whereby the company generates a higher revenue rate compared to pre-game.

We estimate in-play gaming revenue will increase at a 24% CAGR through 2030, compared to pregame increasing at a 10% CAGR over the same time period. We believe revenue will benefit from its ability to take more price in the long term; as a note, iGaming content fees can reach low double digits (of GGR), compared to GENI only taking mid-single digit take rates (blended)."


Summary: Bullish UUUU breaking above key long-term MAs with dual exposure to nuclear and rare metals themes.

$UUUU peeking its head above both 200-week and 50-month moving averages simultaneously. Dual-theme exposure for both nuclear & rare metals. https://t.co/Ny4HpXO1Mj


Summary: Still holding full position in LEU; no shares sold.

@ConnorJBates_ Haven’t sold a single share 😏 https://t.co/HwyOTSqjR3

$LEU More New Highs https://t.co/IpFAdM9BTg


Summary: Still holding CRSP shares at $43.24 cost basis plus Oct $50 calls; ongoing long position.

@TLAMB91 Nice... I still own this one with $43.24 cost on shares (entered 6/18) and I have the Oct $50Cs too


Summary: Bullish on Kratos over AVAV; more optionality and better long-term chart.

Kratos Defense & Security Solutions trades as KTOS on NASDAQ.

@blaketranGG9921 AVAV is great too, do as you please. I feel that Kratos has more optionality and a better long-term chart.

@stocktalkweekly why would i buy this over avav?


We remain bullish on LEU shares and continue to view the company as a "Must Own" for any investor seeking nuclear exposure. As such, we are increasing our price target to $205 (from $145)

Summary: Evercore ISI raises LEU PT to $205 from $145, reiterates Outperform; calls it a must-own for nuclear investors on HALEU monopoly + AI power tailwinds.

CENTRUS ENERGY $LEU price-target raised to $205 (from $145) at Evercore ISI, while maintaining an 'Outperform' rating.

Analyst Nicholas Amicucci says the stock is a "must own" for nuclear investors.

"Private Capital Raise A Positive For Nuclear. Earlier today TerraPower announced a $650MM private funding capital raise which included both new investors, like NVentures, the venture capital arm of NVIDIA, and current investors. The fundraise provides another indication of the vital role nuclear energy will play in powering AI going forward. Importantly, the raise also provides an incremental positive data point for Centrus Energy given its agreement with TerraPower to provide High-Assay Low-enriched Uranium (HALEU) for TerraPower’s Natrium technology based advanced nuclear reactor.

As we outlined, one of the gating factors outlined by NEI CEO Maria Korsnick at its May Nuclear Policy event was private investment in the industry. The addition of NVIDIA to the cohort of investors within TerraPower should provide yet another indication of the tech sectors preference for nuclear’s carbonfree, reliable generation attributes. While the earmarking of the $3.4B of available DOE funds for the build out of a domestic nuclear fuel supply chain remains the most meaningful nearer-term catalyst for LEU, in our view, incremental private investment in Centrus’ SMR partners should also further underscore the value of being the only company with an NRC license for HALEU production to supply commercial and national security needs.

We remain bullish on LEU shares and continue to view the company as a “Must Own” for any investor seeking nuclear exposure. As such, we are increasing our price target to $205 (from $145) which reflects a ~$165 longer-term SWU price and a slightly lower discount rate applied within our discounted cash flow valuation approach.

AI Dominance Requires Nuclear Dominance. Given the 24/7 power profile of AI, the ability to win the AI race begins with the United States ability to unleash its advanced nuclear energy. To support the rapid acceleration of AI, the United States need to secure a resilient, always on and dispatchable power source, ideally one that is immune to weather intermittency and potential pipeline constraints, which is something nuclear can provide.

The nuclear industry overall has already benefited from the administrations Executive Orders, but the continued bipartisan support for increased nuclear power capacity and preference for deployable and reliable power generation from the hyperscaler community continues to drive further interest. Strong Bi-Partisan Support For Nuclear. As was outlined during our conversation with Lightbridge CEO Seth Grae, both sides of the aisle continue to support nuclear as a source of power generation.

The Inflation Reduction Act has been under significant scrutiny of late as the reconciliation bill made its way out the House of Representatives and into Congress. The tax credits associated within other clean technologies (like wind and solar) remain in limbo, despite somewhat similar support from both political parties largely because nuclear has yet to get the kind of advantages wind and solar have already benefitted from, but also more likely due to the type of generation needed to power technologies of the future."


Centrus Energy is uniquely positioned as the only U.S.-owned uranium enricher... We believe Centrus should hold a position in any energy-themed investor's portfolio. Initiating Coverage at Outperform.

Summary: William Blair initiates LEU, OKLO, BWXT at Outperform as beneficiaries of the nuclear renaissance.

NUCLEAR STOCKS CENTRUS ENERGY, OKLO ENERGY, AND BWX TECHNOLOGIES INITIATED AT OUTPERFORM AT WILLIAM BLAIR -- "BENEFICIARIES OF THE NUCLEAR RENAISSANCE" $LEU $OKLO $BWXT

Centrus Energy $LEU -- "Initiating Coverage at Outperform. Centrus Energy is uniquely positioned as the only U.S.-owned uranium enricher, providing advantages in both technology and national security. As the company transitions from a broker of foreign nuclear fuel to a producer and supplier, we expect Centrus to capture significant market share supplying the U.S. commercial nuclear fleet with low-enriched uranium (LEU) and high-assay low-enriched uranium (HALEU). We believe Centrus should hold a position in any energy-themed investor’s portfolio."

Oklo Energy $OKLO -- "Initiating Coverage at Outperform. Oklo is developing a generation IV small modular reactor (SMR) and employing a build, own, and operate strategy that is a standout in the industry. It will accelerate regulatory timelines and improve unit economics by capturing the premium on clean baseload electricity through direct power purchasing agreements. We forecast SMRs to be large participants in the nuclear renaissance with a path toward 50 GW by 2040, and Oklo is best positioned for market adoption; thus, our rating is Outperform."

BWX Technologies $BWXT -- "Initiating Coverage at Outperform. BWX Technologies has a robust position in the commercial nuclear supply chain, especially Canada’s home-grown CANDU reactor fleet. Although it is mostly known as the U.S. Navy’s sole nuclear reactor supplier, we view this steady business as a provider of expertise and capital to expand its commercial nuclear power business, including CANDU and small modular reactors. We are initiating coverage with an Outperform rating as we believe BWXT will be a large beneficiary of the nuclear renaissance."


Oklo is best positioned for market adoption; thus, our rating is Outperform.


we believe BWXT will be a large beneficiary of the nuclear renaissance. Initiating Coverage at Outperform.


reiterate our Outperform rating… bull case fair value of $246 per share, presenting 41% upside from the current share price of $174

Summary: William Blair reiterates Outperform on Centrus Energy, bull case fair value $246/share (41% upside), citing unique position as only U.S. enriched uranium producer.

CENTRUS ENERGY $LEU reiterated at 'Outperform' at William Blair

Analyst Jed Dorsheimer says lack of domestic uranium production is a "national security issue of the highest order", and Centrus Energy has a "bull case fair value of $246/share"

"Action Call. On Tuesday, July 8, we hosted Chief Executive Officer Amir Vexler of Centrus Energy for a fireside chat. We expect investors walked away more confident in Centrus’s unique position as the only unobligated U.S. producer of enriched uranium and in the timeline and capex required to transition the business to this endeavor. We encourage exposure to Centrus as a key beneficiary of the nuclear revival, and reiterate our Outperform rating.

Business Transition to Domestic Enricher. A key topic is Centrus’s transition from an importer/broker of foreign nuclear fuel to a domestic uranium enricher. Centrus commented on the timeline required to fund the development of cascades and highlighted the company’s strategic focus to supply the current demand for LEU and then expand its HALEU capacity as the small modular reactor (SMR) market grows.

SWU Deficit and National Security. The U.S. nuclear fleet requires 15 million separative work units (SWU) of enriched uranium per year. Only 4.3 million SWU are produced in the U.S. by Urenco, which is owned by a consortium of the U.K., Netherlands, and Germany. The rest is imported, with 25% coming from Russia. The lack of domestic production is a national security issue of the highest order. If we include the foreign-owned Urenco as domestic supply, the U.S. needs to increase production by 3.5 times to meet current demand, and 14 times to meet its 2040 goals of quadrupling nuclear power. Centrus presents the only unobligated supplier, meaning it is the only U.S.-owned company and technology, for enriched uranium.

Will Hyperscalers Invest Upstream in Enrichment? Vexler made a salient point that there is no slack in the enriched uranium supply chain, and no new capacity will come online without large offtake agreements. Hyperscalers have already expressed their desire to secure nuclear energy in PPAs, and even directly invested in next-gen SMR companies. The question is, will hyperscalers take another step upstream and secure SWU supply? We saw this from auto OEMs investing directly in lithium mines with offtake agreements, so there is precedent, and we expect conversations are already occurring.

Valuation. Centrus trades at 35x our 2026 EV/EBITDA estimate, above its peers at 24x. In our discounted cash flow scenario analysis through 2040, we estimate a bull case fair value of $246 per share, presenting 41% upside from the current share price of $174."


Summary: Still holding full LEU position at $190s, up 100%+ from $96 entry with no shares sold.

Centrus Energy $LEU now back to the $190s, shares up over +100% from our entry, and I still have not sold a single share. https://t.co/VIHHcq8Q2f

We opened a position in Centrus Energy $LEU last week at ~$96… stock is now $124+ up nearly 30% 🔥 https://t.co/n24iDIlpDm


Summary: Bullish AIP: chart breaking over 200-day MA, move above $9 could accelerate further upside.

@pennycheck Daily chart is an absolute beauty pushing over 200-day. Over $9 can get very interesting. https://t.co/veVi6J95zD

🚨 Pretty big news / DD find
$AIP + $NVDA customer.

Just Disclosed for the first time ever  that $NVDA is a customer for $AIP.

This in my mind has tremendous implications and sheds additional light on some cryptic comments the CFO made at the Greenblatt conference last week. https://t.co/AxWCdeFT1E


Summary: Stifel raises RKLB PT to $34 (from $29), reiterates Buy on Geost acquisition expanding into satellite payload segment.

ROCKET LAB $RKLB PT RAISED TO $34 AT STIFEL

Rocket Lab USA $RKLB price-target raised to $34 (from $29) at Stifel, while maintaining a Buy rating.

"After the close, Rocket Lab announced an agreement to acquire Geost, LLC, an electro-optical and infrared payload development and manufacturing company and provider to high-priority national security satellites for $275M ($125M in cash and $150M in privately placed shares of RKLB, with an earn-out of up to $50M tied to revenue targets).

The transaction is expected to close sometime early in 2H25 and has already been approved by both company boards of directors, but is subject to regulatory (HSR) and standard closing requirements. While no GAAP information was provided, management believes the deal will be neutral to moderately accretive to its adjusted EBITDA in the 2H25.

We are encouraged by this latest announced deal, and its strategic rationale where Rocket Lab is acquiring key technologies to enter into the satellite payload segment, creating a new category and positioning the company as a disruptor for national security space."


Summary: Deutsche Bank initiates IMCR at Buy with $65 PT on favorable risk/reward, Tebentafusp SOC foundation, and pipeline upside.

IMMUNOCORE $IMCR INITIATED AT 'BUY' AT DEUTSCHE BANK WITH $65 PT

Immunocore Holdings $IMCR initiated at 'Buy' at Deutsche Bank, with a $65 price-target:

"Believing is Seeing for IMCR’s ImmTAX (Immune Mobilizing Monoclonal TCRs Against X disease) platform – Initiating with a Buy at DCF based price target of $65/sh.

Tebentafusp (aka KIMMTRAK) established itself as the standard of care (SOC) for HLA-A*02+ 1L metastatic Uveal Melanoma (mUM) with its OS benefit. Uniquely, ORR and PFS were not very differentiated, which goes to show that current radiological techniques and RECIST criteria are not apt at reflecting IMCR’s ImmTAC platform potential to reduce ctDNA and provide overall survival (OS) benefit.

As for IMCR’s stock, we think current valuation offers a favorable risk/reward where Tebentafusp’s niche in 1L mUM provides a foundation / floor valuation and duration - per IMCR’s 2024 10K, it seems Teben’s patent is likely to be extended to 2035. We see Teben’s expansion into 2L+ Cutaneous Melanoma (mCM) providing upside - Ph3 data in 2H26. Acknowledge 2L+ CM is distinct from mUM, but it does look Teben’s disease control rate is showing signs of improved Overall Survival rates (1-year rate of 75% vs 55% for SOC).

We also think Brenentafusp (PRAME x CD3) has some modest potential to expand IMCR’s reach into Platinum Resistant Ovarian Cancer (PROC) in 2026. We’re less sanguine on Brene’s 1L CM opportunity given the high dataset bar set by BMY and REGN."


Summary: Holds NBIS as a core position at $23 cost basis; agrees it can go much higher with right catalysts.

@beth_cronk It's a core position for me now, so I'm comfortable with my $23 cost basis, but not buying any more! I have full-size and happy with the weighting in my portfolio. But I agree, with the right catalysts it can go much higher!

@stocktalkweekly It's still not too late to buy $NBIS


Summary: Shares bullish news on Amazon's humanoid robot delivery trials via Rivian vans, implying positive outlook for AMZN.

*AMAZON TO LAUNCH HUMANOID ROBOT DELIVERY TRIALS $AMZN

Amazon is finalizing "Humanoid Park", an indoor obstacle course at its San Francisco office to test humanoid robots for delivery. Amazon intends to trial the humanoids in its fleet of 20,000+ Rivian vans -- The Information


Summary: JPMorgan upgrades BE to Buy/Overweight with $33 PT on fuel cell tax credit qualification, upside to consensus revenue/margin estimates from FY26.

BLOOM ENERGY $BE upgraded to 'Buy' (from Neutral) at JPMorgan, with a $33 price-target (from $18)

Analyst Mark Strouse says he believes there is upside to consensus revenue & margin estimates:

"We are upgrading BE to Overweight from Neutral. With fuel cells unexpectedly qualifying again for 48E tax credits as part of the OBBB, we believe there is upside to consensus revenue and margin estimates beginning in FY26. As competing gas turbine pricing and lead times remain elevated, we believe the tax credits for fuel cells can push hesitant BE customers over the finish line and expect order activity to increase accordingly.

We also tactically expect BE’s 2Q messaging to be relatively more upbeat than our coverage average given final OBBB law is now in place, though there is still some uncertainty regarding safe harbor rules following a July 7 Executive Order that could keep a lid on sentiment for solar and wind. We are updating our model and introducing FY27 estimates with this note. We are establishing a YE26 price target of $33, up from our prior YE25 target of $18."


Summary: Shares Needham Buy reiteration on CORZ with PT raised to $18 on CoreWeave demand backdrop and attractive valuation vs peers.

CORE SCIENTIFIC $CORZ price-target raised to $18 (from $16) at Needham, while maintaining a 'Buy' rating:

"We believe the market has growing comfort with CoreWeave as a counterparty and continue to believe there is a strong demand backdrop which should vastly outstrip supply over the next 5 yrs and be positive for our bitcoin mining/HPC universe. We compare the three data center operators with signed leases with CoreWeave:

With respect to peers, CORZ looks attractively valued with some of the strongest sites (for inference AI workloads) yet is trading at a discount. We are raising our PT and increasing our tgt multiple to reflect this growing investor confidence in the underlying lessee.

We maintain our prior estimates and increase our target multiple to 16x our discounted '26 EBITDA, which equates to $18 target price. We also look towards CORZ' pipeline and additional site expansion oppties longer term."


Summary: Long GENI via stock + calls; NFL exclusive data deal extension is a major catalyst, EBITDA growth has legs, and margin expansion likely as market re-rates it as SaaS.

Ever wish the NFL was a publicly traded company? Me too. In my view, the closest way to get exposure to the NFL on the public markets currently is Genius Sports $GENI

Genius, for those unfamiliar, is a sports-betting data provider in an industry that is essentially a duopoly between them and Sportradar $SRAD.

Yesterday, Genius Sports secured an (early) extension of their *exclusive* data distribution deal with the NFL for real-time stats & sports-betting data thru 2029.

The company is a sub $2.5 billion market cap doing $575M in annualized revenue based on Q1 '25 ($702M if you annualize Q4 '24), growing total group revenue +20% y/y & sports-betting revenue +44% y/y. As of previous quarter, EPS still slightly negative but adjusted EBITDA at $20M (3x y/y) and EBITDA margin to 14% (from 6% last year).

Genius has exclusive data distribution rights for other popular leagues, too.

- Premier League & English Football League thru 2029
- NCAA postseason events thru 2032
- PGA Tour
- NASCAR

It's a "winner-agnostic" way to play sports-betting. For those who don't know what that means, it means it doesn't matter to them which sportsbooks (Draftkings, Fanduel etc.) win out the customer acquisition war in regional or national markets. They have to get the data from Genius anyway.

From a technical perspective the monthly chart is very explosive. The 50-month moving average emerged back in December 2024, and since then it has acted as perfect support for price for 5 & a half consecutive months. The 9-month EMA crossed over the 50-month in March of this year, and price clung to it beautifully. A break back above $11.50 would open up massive range for the stock.

I have traded Genius $GENI successfully many times in the past and always considered a longer-term position because I thought the business model was promising.

I believe yesterday's early extension of the exclusive NFL deal is a major catalyst as a testament to their staying-power in this business and a validation of the idea that their dramatic rise in EBITDA has legs.

I also believe there is an opportunity for margin expansion as the market begins to recognize Genius as a SaaS company with a massive total addressable market, with the undercurrent of the inevitable expansion of sports-betting as an accelerant.

As always, this is not financial advice and I am simply sharing the reasons why I have taken a position in Genius Sports.

I am in common stock and $10 calls across various expirations. I have a level of maximum risk on this position (if price falls below the 200-day moving average). As with all SMID cap stocks, you should expect this stock to be highly volatile and more risky than stalwart, bluechip names.

Cheers and thanks for reading 🍻

---

Hey @stoolpresidente here’s an idea if you want to buy a decent stock for a change


Summary: Holds HOOD as a long-term position; bullish on Vlad's execution.

@amitisinvesting Yeah long-term position for me... Vlad is firing on all cylinders. Next step is to move my assets to RH 😂 maybe one day when they improve active trading tools

@stocktalkweekly LFG 🙌

Under $20 really could be a generational average

my entire sister has her roth ira in $HOOD at $17 haha


TRUIST - $210 PT - BUY --- EVERCORE - $190 PT - BUY --- KEYBANC - $190 PT - BUY --- JEFFERIES - $185 PT - BUY --- WELLS FARGO - $185 PT - BUY --- BERNSTEIN - $185 PT - BUY --- BANK OF AMERICA - $180 PT - BUY --- STIFEL - $180 PT - BUY --- CITIBANK - $180 PT - BUY --- TD COWEN - $175 PT - BUY --- JPMORGAN - $170 PT - BUY --- MIZUHO - $170 PT - BUY --- RAYMOND JAMES - $165 PT - BUY --- NEEDHAM - $160 PT - BUY

Summary: 14 of 16 Wall Street analysts reiterate Buy on NVDA with PTs ranging $160–$210, citing Blackwell ramp, improving yields, and demand visibility despite H20 export controls.

*WALL STREET COMMENTS ON NVIDIA EARNINGS $NVDA

Analyst opinions listed in order of price-targets.

TRUIST - $210 PT - BUY --- "NVDA just overcame a huge hurdle. Excluding export controls, NVDA's CQ1 result and its CQ2 guidance would have beaten consensus, handily. As we deal in reality, the export controls made the CQ1 beat modest and, yes, NVDA's CQ2 guide was slightly below consensus. Still, a great result considering the circumstances. Aligned with feedback from our industry contacts, demand for NVDA's gear from CSPs, enterprises, and sovereigns, is still increasing. The $50B China TAM is on hold for now, but our estimates still go higher (margins). CY26 EPS goes to $5.99 (from $5.87). PT to $210 (from $205) based on 35x EPS (10x discount to high-growth semi peers)."

EVERCORE - $190 PT - BUY --- "Still a Top Pick Post AprQ Report. We continue to view NVDA as a top pick post a 9% AprQ EPS beat and JulQ EPS outlook that was 1% below consensus. Our sense is that investor concern has centered on concerns of Blackwell chip/system delays, hyperscaler CapEx digestion period, and competitive threats from ASICs. We think NVDA addressed these concerns on its earnings call, namely that 1) its DC business grew by 73% YY, 2) Blackwell system yields are improving and accounted for 70% of DC revs, 3) Major hyperscalers are deploying on average 72,000 Blackwell GPUs per week, and 4) its nextgen Blackwell, GB300, should ramp production later this quarter. These are consistent with our own checks (note here) that hyperscalers are not slowing down CapEx, they want larger LLMs, demand is increasing from Tier 2 CSPs both domestically as well as internationally, and NVDA remains the AI ecosystem of choice."

KEYBANC - $190 PT - BUY --- "Comparing these results to cons is somewhat difficult as Street ests reflect a blend of ests that have removed H20 revs. However, we view F1Q (Apr) results, and esp F2Q (Jul) guidance, as very strong. Regarding China, NVDA noted F2Q excludes $8B in H20 revs, which, if we compare to cons before the China ban of $47.9B, would imply the comparable guide would have been ~$53B in revs and well above. Blackwell revs contributed nearly 70% of Data Center compute revs, which grew 73% y/y. Additionally, NVDA noted it is seeing a significant improvement in GB200 NVL72 manufacturing yields, noting hyperscalers on avg are deploying nearly 1K NVL72 racks/week or 72K Blackwell GPUs per week. We're encouraged by these results and are fine-tuning ests due to just-released results. Remain OW."

JEFFERIES - $185 PT - BUY --- "The biggest issue for the stock was the disconnect between Blackwell sales and GB200 shipments but that is now in the rearview as NVDA noted multiple hyperscalers ramping 1k NVL72s/week. We would not run-rate several thousand NVL72 per week but the point is that whatever inventory that built up is clearing fast. The GB300 started sampling with major CSPs earlier this month with production volume set for July quarter and should benefit from the GB200 improvements. On the demand side, NVDA noted line of sight to 10GW+ of projects ($40-50/GW opportunity) as Sovereign AI traction is accelerating on the back of significant commitments from both UAE and Saudi Arabia. Networking revenue also looks better with Spectrum-X adding two new customers (GOOG/META) and NVLink exceeding $1B revenue in April quarter. Altogether 2H25 shaping up nicely for NVDA with likely beat/raises from here, while the setup for the rest of AI names becomes more challenging."

WELLS FARGO - $185 PT - BUY --- "F2Q26 Guide: NVIDIA is guiding F2Q26 rev at $45B +/- 2%, GM% at ~72% +/- 50bps, and ~$4B opex vs prior Street (VisibleAlpha) at ~$42.8B / 73.1% / $3.9B. With an OI&E at ~$450M and a 16.5% (+/- 1%) tax rate, we arrive at an implied F2Q26 non-GAAP EPS at ~$0.94-$1.02 (prior Street @ $0.99/sh). NVDA expects modest q/q growth across all platforms. With shares of NVDA now trading at 24x and 21x our CY26 & CY27, respectively — or more notably trading near a trough relative P/E to SOX (2 st. deviations below 5-yr median), we reiterate our OW rating and $185 PT. We think investor sentiment will now shift back toward a path to +$6/sh. CY26 EPS. We move our FY26, FY27, and FY28 ests. from $189.6B / $4.07, $242.0B / $5.60, and $285.9B / $6.58 to $200.6B / $4.37, $256.9B / $6.00, and $303.1B / $7.05. Maintain $185 PT."

BERNSTEIN - $185 PT - BUY --- "Amid a messy quarter NVIDIA is comporting themselves extremely well. The China headwind is unpleasant and frustrating, but we salute management for trying to sugarcoat neither the near-term impact nor the potential longer term implications, and it appears fully flushed out of numbers (hence representing possible upside if and when the company can manage to work around the new constraints). And the general outlook and environment overall seems very encouraging (and better than last quarter) as the Blackwell ramp takes off, rack supply eases into the 2H, and demand outlook into year-end (and probably into CY26) looks to be solidifying, and robust as ever as compute requirements continue to move upward."

BANK OF AMERICA - $180 PT - BUY --- "Three major takeaways from the Q1 call: 1) China derisked, with $15bn in 1H sales of H20 product now already in the model, 2) Blackwell racks in full production, with every large hyperscaler now ramping close to 1K racks/week, 13K racks/quarter or ~$30bn+/q at $2.5mn+ rack ASP (or $100bn+ across the top few hyperscalers, though NVDA didn’t quantify further), and 3) NVDA confident in GM recovery back to mid-70s % sometime later in the year, another sign of improving demand and rack-scale execution. Networking also returned to low/mid-double-digit of Data Center revenue in Q1, as NVDA’s complete portfolio of NVLink (Scale-Up), Quantum/Spectrum (Scale-Out), and BlueField (DPUs/NICs) in rack-scale systems is now fully ramping across multiple hyperscalers (inclusive of new Google/Meta win for Spectrum-X) – an incremental AVGO headwind. We reiterate Buy on top pick NVDA, raising our FY26/27/28E pf-EPS by 6%/2%/12% to $4.21/$5.87/$7.23, and PO to $180 from $160 on higher 30x PE vs 28x prior given faster EPS growth."

STIFEL - $180 PT - BUY --- "NVDA beat F1Q expectations despite $2.5bn in unfulfilled H20 revenue. Adjusted gross margin (excluding H20 related inventory and purchase obligation charges) of 71.3% was slightly above management guidance as well. Looking ahead, F2Q revenue guidance of $45bn was better than feared, in our view and would have been $8bn higher if not for the H20 export restriction. On an apples to apples basis, we believe that non-China DC revenue is on track to increase ~30% sequentially as the GB200 ramp progresses. NVDA noted that GB300 systems began sampling in early May with a transition to production shipments later this quarter. We expect a smooth transition to GB300 and, to that end, NVDA maintained its outlook for a recovery to mid-70s gross margins by fiscal year end. We continue to expect a strong back half of F2026 as NVDA continues to benefit from the rapidly changing AI landscape."

CITIBANK - $180 PT - BUY --- "NVDA reported Apr-Q results in-line and Jul-Q sales of $45B ~$1B above our preview expectations clearing the final hurdle of the China H20 ban transition quarter. Moreover, Blackwell sales of $24B topped our $20B expectations and management maintained mid 70’s gross margins target on improving Blackwell profitability with no major tariff impact. As such, with margins expanding thru Jan-Q, we now expect NVDA stock to break its range bound trend since mid-last year and likely make a fresh 52 week high. We see Citi’s Silicon Valley Bus Tour next week and GTC Paris June 11-12 where we expect sovereign AI Europe announcements as positive catalysts for the stock. NVDA talked about line of sight to tens of gigawatts on AI factories including sovereign AI with 1GW ~$50B data center opportunity. We adjust FY26/27/28 EPS flat/+9%/+5% on higher gross margins and lift TP to $180 on consistent 30x P/E. Maintain Buy."

TD COWEN - $175 PT - BUY --- "A strong print and guide was well above investor expectations after accounting for H20 write-downs. Rack-scale concerns are receding with strong commentary on NVL deployments at hyperscalers. Bears will likely now shift to the GB300 transition as the next wall of worry, in addition to perpetual cloud digestion concerns. Our numbers go higher again. Reiterate Buy, Top Compute Pick, PT to $175."

JPMORGAN - $170 PT - BUY --- "NVIDIA reported solid Apr-Qtr revenues of $44B (above ours/consensus estimates of $43B) even with ~$2.5B of lost H20 China GPU shipments due to China restrictions (restrictions to China went into effect on April 9th) while margins/EPS were impacted by the $4.5B of H20 inventory write-downs/purchase commitments driving lower GMs (61% versus prior guide of 71%) and EPS of $0.81 (versus consensus of $0.93). For the Jul-Qtr, the team guided revenues to $45B, below consensus ($46B) as sell-side estimates did not accurately reflect the H20 shipment restrictions, but better than our expectations of $41-$43B taking into account the H20 restrictions. Ex-H20 shipments, we estimate that July quarter datacenter revenues are growing ~16% Q/Q on continued strong spending from its customers to support their AI/accelerated compute initiatives (both training/inference) and the continued strong production/deployment ramp of its Blackwell datacenter platform.

Blackwell shipments are expected to continue to ramp higher through the year and the team remains on track to ramp its next-gen Blackwell Ultra (B300/GB300) near the end of this quarter. We still believe there is ~$5B in H20 shipments that were scheduled for shipments in the 2H which will not be shipped due to April H20 restrictions. In Networking, revenues inflected strongly (Q/Q and Y/Y) in the April-Qtr as the team benefitted from strong networking (NVLink switch) content in NVL72 rackscale platforms (although TTM networking revenues are up only 37% versus compute revenues which are up 113% - we will continue to monitor the sustainability of the networking inflection closely). Demand for Blackwell is very strong and will continue to outstrip supply for several quarters, although the team and its value-chain partners are now shipping 1000 NVL72 racks per week -- strong production execution.

GM guidance (72%) was 30 bpts above consensus expectations as the team aggressively ramps its higher margin Blackwell platforms on increasingly improving yield/cost dynamics. Given recent elimination of the diffusion rule and recent mega datacenter build-out announcements (UAE, Saudi Arabia, Taiwan, etc), we believe the team has good visibility for continued strong growth through CY26. Bottom line, the team continues to maintain a 1- 2 step lead ahead of competitors with its silicon/hardware/software platforms and a strong ecosystem, and the team is further distancing itself with its aggressive cadence of new product launches and more product segmentation over time. We adjust our forward estimates, introduce our CY26 estimates, and maintain our Dec-25 PT of $170, and reiterate our OW rating."

MIZUHO - $170 PT - BUY --- "NVDA reported a slightly better AprQ rev of $44.1B (cons. $43.3B) and guided in line JulQ to $45B BETTER than some concerns with H20 headwinds. We note: 1) Key DC Revs inline ~$39.1B up 10% q/q (up 73% y/y), with Blackwell revs coming in at ~$24B (est of ~8k NVL72 racks); 2) Blackwell 70% of shipments, U.S. was 47% of revs, Hyperscalers at <50% of revs, with GB300 Ultra shipping in the JulQ; 3) JulQ Blackwell/GB200 ramps accelerating with CSPs standing up >1k racks/week; and 4) AprQ Networking was up 64% q/q with NVLink + SpectrumX at >$3B of revenue. NVDA noted a $4.5B charge to inventory for H20, with $2.5B of revenues unable to be shipped, which we had noted, and expected $8B revenue impact in JulQ. Reiterate Outperform, adjust estimates/PT to $170 with China headwinds partially offsetting Blackwell ramps."

RAYMOND JAMES - $165 PT  - BUY --- "F1Q results and F2Q outlook were better than our recent expectations, especially considering the larger than expected impact from H20 restrictions. Blackwell racks are in full production as early yield issues are now behind, which also appears to be helping gross margins. Management highlighted a surge in revenue-generating inference services, suggesting that AI monetization is accelerating. Networking rebounded strongly after a 2-quarter decline driven by NVLink while Spectrum-X Ethernet switch added two new customers (META, GCP).

Gaming was another area of strength on the back of new products and improving supply. Looking ahead, management did not specifically comment on 2HCY25, but appears to have “line of sight to projects requiring 10s of gigawatts of NVDA AI infrastructure in the not-too-distant future” (each gigawatt potentially a ~$50B opportunity). China (H20) is now de-risked and management clarified that >99% of data center GPU revenue billed to Singapore was for U.S. customers, putting to rest concerns about additional export controls. We raise estimates, raise PT from $150 to $165, and reiterate SB1."

NEEDHAM - $160 PT - BUY --- "NVIDIA delivered an F1Q26 beat, but a miss on the F2Q26 guide due to the impact of H20 export controls. Our key takeaways include: 1) The H20 lost opportunity is larger than expected, as the company had $8BN of H20 orders on the books for F2Q that will not ship. China DC revenue is expected to decline an insignificant level; 2) Blackwell contributed nearly 70% of DC Compute revenue, with the transition from Hopper nearly complete. Major hyperscalers are standing up 1,000 NVL72 racks per week, a number expected to move higher through the quarter; 3) GM ex. the H20 write down was better than expected as Blackwell profitability improves; and, 4) Networking revenue increased to $5.0BN, driven by both Scale-Up and Scale-Out networking solutions. Our PT remains $160, based on a ~27.5x P/E multiple of our new FY27/CY26 NG EPS estimate of $5.80."

DEUTSCHE BANK - $145 PT - NEUTRAL --- "NVDA weathered the trade restrictions to deliver a solid report/guide (F1Q/F2Q revenues of $44b/$45b vs. DBe of $44b/$44b), albeit with both revenues (-$2.5b headwind in F1Q/and $8b headwind in F2Q) and GM (-1030bps headwind) impacted by the curtailing of the co's China business. Strength continues to be driven by the ramp of the co's Blackwell GPUs ($24b vs $11b in F1Q), albeit with a surprising lift coming from the co's DC Networking ($5b; +64% q/q) and Gaming ($3.8b, +48% q/q) businesses as well. On the China front, NVDA reiterated their view that AI shipment restrictions are counterproductive and still hopes to be able to address the $50b TAM at some point, albeit with no restriction-compliant products announced nor included in the F2Q guide (~$8b reduction in F2Q, but potentially a future upside driver)."

DA DAVIDSON - $135 PT - NEUTRAL --- "We maintain our NEUTRAL rating and raise our price target from $120 to $135 on NVIDIA following mixed earnings results that saw better than expected top-line numbers, but notable impact from the lack of H20 sales into China in Q1 and Q2. It is our belief that the Street is under-accounting Chinese contribution to NVIDIA revenue and that this topic represents the largest overhang on the stock, which will continue until we have an official position from the Trump administration that will give us resolution on the matter in one direction or the other."


Summary: Strongly bullish GENI on golden cross, record volume across all timeframes, and upside gap fill setup.

$GENI doesn't get prettier than this. All moving averages simultaneously crossing 200-week (including 50/200 golden cross). Highest daily, weekly, and monthly volume ever. Climbing into a big gap to the upside. https://t.co/ugpkUAs8dh

Ever wish the NFL was a publicly traded company? Me too. In my view, the closest way to get exposure to the NFL on the public markets currently is Genius Sports $GENI

Genius, for those unfamiliar, is a sports-betting data provider in an industry that is essentially a duopoly


Summary: Still fully long LEU, now highest portfolio weight, with plan to add more on dips.

Centrus Energy $LEU shares are now up +132% from our $96.94 entry in late May. Still have not sold a single share, and position has become highest weighing in the portfolio. Goal is to buy more on any significant drawdown. Tremendous cost-basis flexibility here. WHAT A STOCK🔥 https://t.co/wXVKrIiHlr


Summary: Still holding NBIS as a core position at $55+; bullish on continued strength from Clickhouse, Toloka, and Avride.

In less than 2 months since I initiated a position in Nebius $NBIS at $23.92, the stock is now $55+ and my shares are up +132%

This is a core position for me, and has been a wonderful performance accelerator for the portfolio. Clickhouse, Toloka & Avride continue to shine. https://t.co/CXWzNXObLl

Last week, on our premarket prep call on May 6, we discussed the Northland initiation on Nebius Group $NBIS with members, with the stock was trading under $24. Last Friday when the Clickhouse news came out, we added to the position.

Today, the stock is up +17%. Great timing! ✅


Summary: Shares Citi initiation of DLO at Buy with $14.60 PT on EM payment platform growth and dividend policy.

DLOCAL $DLO INITIATED AT 'BUY' AT CITIBANK WITH $14.60 PT

DLocal Limited $DLO initiated at 'Buy' at Citibank, with a $14.60 price-target:

"We are initiating coverage of DLO with a Buy/HR rating, and a 12M FWD TP of US$14.60/share. dLocal is a cross-border payment platform, focused on EM economies, with TPV expanding at a fast pace.

Global competition remains concentrated in developed markets, making DLO the certain choice for merchants’ expansion towards EM. Also, the company announced its dividend policy, planning to distribute 30% of FCF annually, starting in 2026 – which should bring extra shareholders’ returns. DLO is currently trading at 16x 2026E P/E."


we reaffirm our Buy rating and would recommend using any transaction-related weakness to establish or add to positions

Summary: Stifel reiterates Buy on KTOS with $52 PT; recommends buying transaction-related weakness given rich opportunity set in hypersonics, cruise missiles, and unmanned systems.

KRATOS $KTOS reiterated at 'Buy' at Stifel, with a $52 price-target.

Analyst Jonathan Siegmann says that four out of the last five offerings were "excellent buying opportunities":

"After the market close, Buy-rated KTOS announced a $500m primary equity share offering. While the specific projects that will be receiving additional funding are unknown, we think KTOS enjoys a rich opportunity set to make incremental investments behind growth. We reaffirm our Buy rating and would recommend using any transaction-related weakness to establish or add to positions.

We favor companies that are investing in organic growth opportunities in new defense tech space and believe KTOS has some particularly promising potential investment options in hypersonics, cruise missile engines, and unmanned systems. While it might be easier to underwrite an offering with greater specifics on KTOS's intended new investments, we like KTOS's current rich opportunity set.

As one example of KTOS's pending new investments, the company announced a new 50,000 sq ft facility to produce five new turbojet engines in Oklahoma. These turbojet engine capacity investments accelerate the production and market introduction of new small affordable engines intended for new unmanned aerial systems and collaborative combat aircraft produced in partnership with GE Aerospace.

Some pushback we received from investors is KTOS is just opportunistically selling equity, and this latest offering should be viewed as a concerning sign. We would counter this is not consistent with history as four out of five last equity offerings over the last 10 years were excellent buying opportunities. The one exception was in 2020 (share price lower than offering on a 24-month basis)."


got back in at $96 on May 22 after-hours and haven't sold a single share. Largest position by weighting for me. One of the rarest assets on market.

Summary: Holds LEU as largest position, hasn't sold a share; views it as one of the rarest assets on market.

@1ChartMaster Yup! Owned in $40s, sold in $80s last year (have many old tweets on the name) and got back in at $96 on May 22 after-hours and haven’t sold a single share. Largest position by weighting for me. Would love big earnings dip to double position. One of the rarest assets on market.

$LEU nice follow through day. https://t.co/hu4DqeU4yU


Summary: Bullish TLN: two new plant acquisitions could boost EPS 40%, calling it a game changer.

@1ChartMaster Acquired two new plants that could boost EPS by 40%. Game changer.

$TLN What's the story here?   New ATH on 3x volume. https://t.co/UT6TiEMZIo


Summary: Ongoing long position in HOOD; hasn't sold any shares.

@1ChartMaster Still haven’t sold a share

$HOOD buy right and sit tight. 💰 https://t.co/gZALwRbLx9


Summary: Author endorses BTC miners GLXY, IREN, CIFR, RIOT as repricing plays on the CORZ-CRWV buyout premium thesis.

Were you paying attention? $GLXY $IREN $CIFR $RIOT https://t.co/hRGIPoUdgP

If the $CORZ - $CRWV buyout goes through at the premium Wall St. is expecting, a repricing will be needed for most BTC miners & HPC stocks.

$IREN
$GLXY
$RIOT
$MARA
$CLSK
$CIFR
$WULF
$HUT

Almost all them are *highly* shorted (25%+), and the daily chart setups are very strong.


MSTR created the segment, and it has a Bitcoin stack that is unlikely to ever be matched by another entity... MSTR a must-own name in this space, in our view

Summary: Cantor Fitzgerald raises MSTR PT to $680; analyst calls it a must-own on path to 1M BTC; also highly confident BTC reaches $1M.

STRATEGY $MSTR price-target raised to $680 at Cantor Fitzgerald.

Analyst Brett Knoblauch says Saylor's Strategy is highly likely to be one of the largest companies in the world, with 1 million Bitcoins worth $1 million each:

"MSTR created the segment, and it has a Bitcoin stack that is unlikely to ever be matched by another entity. Assuming MSTR acquires ~$20bn worth of BTC a year, this puts MSTR on track to reach 1m BTC in just over three years, and that assumes BTC compounds at a 30% CAGR. The sheer size of MSTR's BTC stack combined with capital markets innovation makes MSTR a must-own name in this space, in our view. If BTC is going to $1m, which we think is highly likely at some point in the future, MSTR could be one of the largest companies in the world."


If BTC is going to $1m, which we think is highly likely at some point in the future


Summary: Bullish HII on breakout from consolidation, targeting $250+.

Huntington Ingalls, beautiful break out of this consolidation now $250+ $HII https://t.co/kG3yjJhBvL

Does consolidation get any cleaner than this?

Huntington Ingalls $HII weekly https://t.co/Z6DEwf76or